Introduction
============

Endothelial dysfunction plays a critical role in the development of diabetic complications including diabetic cardiovascular disorders ([@B20]; [@B39]; [@B63]; [@B10]). A growing body of evidence suggests that abnormality of vascular endothelium can be individually or collectively promoted by various risk factors occurred in diabetes such as oxidative stress, inflammation, hyperglycemia, and hyperlipidemia ([@B56]; [@B10]; [@B58]). Insulin resistance closely associated with the pathogenesis of diabetes and early heart diseases has also been implicated in endothelial dysfunction ([@B56]; [@B28]). Importantly, insulin resistance and endothelial dysfunction appear to affect each other by several signaling pathways and precede the development of overt hyperglycemia in diabetic individuals ([@B20]; [@B4]; [@B28]). Therefore, targeting insulin resistance of vascular endothelial cells may bring to bear beneficial metabolic effects for preventing the diabetic-related cardiovascular diseases.

Curcumin, a major bioactive component from ancient medicinal herb *Curcuma longa* L., has shown strong ability to improve diabetes and diabetic complications, due to its physiological and pharmacological properties such as anti-oxidative stress, anti-inflammation, and anti-insulin resistance activities ([@B29]; [@B49]; [@B59]). Numerous *in vitro* and *in vivo* studies have documented that curcumin sensitizes insulin action or activates insulin signaling under various pathological and pathophysiological conditions ([@B7]; [@B61]; [@B66]; [@B68]). In contrast, high concentration of curcumin has been reported to directly or indirectly inhibit insulin signaling pathway and glucose transport in 3T3-L1 adipocytes under normal culture condition ([@B24]; [@B18]; [@B69]). These studies suggest that impacts of curcumin on insulin signaling may be dependent on curcumin concentration, cell types, or physiological and pathophysiological conditions of targeted cells. Although curcumin has been reported to inhibit high glucose-induced proliferation of human retinal endothelial cell ([@B55]) and also display beneficial impacts on diabetes-induced endothelial dysfunction ([@B54]; [@B60]; [@B49]), the potential impacts of curcumin on insulin resistance of vascular endothelial cells and its underlying mechanism(s) remain poorly understood.

Endoplasmic reticulum (ER) is one of the major sites for synthesis, folding, maturation, and translocation of most intracellular protein. Protein synthesis and folding processes can lead to accumulation of unfolded or misfolded proteins in the ER lumen, and thus initiate proteolytic mechanisms to remove unfolded or misfolded proteins, as well as aggregated proteins. The process of degradation and clearance of proteins from the ER system is called ER-associated degradation (ERAD), including ubiquitin/proteasome ERAD (I) and autophagy/lysosomal ERAD (II) ([@B15]; [@B34]). If unfolded or aggregated proteins are largely accumulated in the ER lumen, an adaptation program known as unfolded protein response (UPR) will be triggered to increase the ability of ER to fold and degrade proteins. Long-term or inappropriate UPR has a direct causal relationship with insulin resistance ([@B46]; [@B23]). Previous studies have shown a significant association between ER stress and insulin resistance in endothelial cells ([@B38]; [@B19]).When this ER stress is blocked pharmacologically, a complete recovery of insulin sensitivity is achieved ([@B51]). Interestingly, curcumin acts as an inhibitor of both proteasome and ER stress ([@B48]; [@B22]; [@B1]; [@B6]; [@B57]; [@B66]). Given that the proteasome pathway and autophagy has been demonstrated to interact each other ([@B35]; [@B26]; [@B65]), we rationally and logically speculated that curcumin might maintain ER proteostasis through activating autophagy, leading to suppression of ER stress with subsequent improvement of insulin sensitivity. This hypothesis would be studied in human umbilical vein endothelial cells (HUVECs) treated with saturated fatty acid palmitate.

Materials and Methods {#s1}
=====================

Antibodies and Reagents
-----------------------

Antibodies to Akt (\#9272), GLUT4 (\#2231), IRS-1 (\#2382), caveolin-1 (\#3238), PERK (\#3192), eIF2α (\#9722), CHOP (\#2895), XBP-1s (\#12782), and phospho-specific antibodies to Akt Thr308 (\#9275), IRS-1 Ser307 (\#2381), and eIF2α Ser 51 (\#9721) were from Cell Signaling Technology (Beverly, MA, USA). Anti-ubiquitin (ab7780), PERK Thr982 (ab192591), JNK (ab112501), and JNK1 Thr183 (ab47337) antibodies were obtained from Abcam Inc. (Cambridge, MA, USA). Anti-LC3 (M152-3) and Atg5 (M153-3) monoclonal antibodies were purchased from MBL (Nagoya, Japan). Bafilomycin A1 (BFA, B1793) and curcumin (C1386) were from Sigma-Aldrich Corp. (St. Louis, MO, USA). The Fluorometric substrates of proteasome Suc-LLVY-AMC (S-280), Suc-LLE-AMC (S-230), AC-RLR-AMC (S-300) were purchased from Boston Biochem (Cambridge, MA, USA).

Cell Culture and Treatment
--------------------------

Primary HUVECs were purchased from Invitrogen (Carlsbad, CA, USA) and cultured in phenol red-free Medium 200 (Cat. no. M-200-500; Invitrogen) containing 1% low serum growth supplement (LSGS), 100 μg/ml streptomycin, and 100 units/ml penicillin at 37°C and 5% CO~2~. Palmitate acid (P0500, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in ethanol, mixed with 20% of free fatty acid (FFA)-free BSA, and then incubated overnight at 4°C. Insulin resistance was induced as previously described ([@B19]). Briefly, HUVECs were plated in 6-well plates or 60 mm dishes until cells have reached 80% confluence and then incubated with serum-free Medium 200 for another 6 h before palmitate supplementation. After treatment with palmitate, cells were stimulated with 100 nM insulin for 10 min. The same concentration of ethanol mixed with 20% of FFA-free BSA was served as control.

Glucose Uptake
--------------

Glucose uptake was determined using Glucose Uptake Colorimetric Assay Kit (ab136955, Abcam, Cambridge, MA, USA) according to the manufacturer's instruction. Measurements were performed at least three replicates and then averaged.

Preparation of Plasma Membrane
------------------------------

Plasma Membrane Protein Extraction Kit (Abcam, Cambridge, MA, USA) was used to obtain plasma membrane (PM) fraction from the cells, according to the manufacturer's protocol. PM purity was determined by expression of membrane marker caveolin-1.

Small Interfering RNAs (siRNAs) and Transfection
------------------------------------------------

The siRNA targeting human ATG5 (NM_001286106) was synthesized by QIAGEN China (Shanghai) Co., Ltd (Shanghai, China). The most effective sequences of siRNA and its paired control used in the experiments were as follows: ATG5, 5′-AACACCTCTGCAGTGGCTGAGTGAA-3′, scramble control, 5′-AACTCTCGACGCGGTGAGTTCAGAA-3′. Transfection was performed with 120 pM of siRNA using Lipofectamine^®^ RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The knockdown efficiency was assessed by western blot.

Peptidase Activity Assays
-------------------------

Proteasomal peptidase activities in HUVECs were measured as described previously ([@B50]; [@B71]). Briefly, the lysate was obtained using cytosolic extraction buffer (containing 50 mM HEPES, pH 7.5, 20 mM KCl, 5 mM MgCl~2~, 2 mM ATP, 1 mM DTT, 0.025% digitonin) and then centrifuged at 10,000 × *g* for 10 min at 4°C. The supernatants were collected for determination of protein concentration and peptidase activity assays. The synthetic fluorogenic peptide substrates Suc-LLVY-AMC, Suc-LLE-AMC, and AC-RLR-AMC were used for assaying chymotrypsin-, caspase-, and trypsin-like activities of 20S proteasome, respectively. For assay specificity, 1 μM of proteasome inhibitor MG132 was incubated with the extract. After 90 min of incubation at 37°C, the fluorescence intensity was read using fluorescence spectrometer (Perkin Elmer precisely LS 55, Billerica, MA, USA) at an excitation wavelength of 350 nm and emission wavelength of 440 nm.

Western Blot and Protein Aggregation Assay
------------------------------------------

The cell lysates were extracted by lysis buffer (containing 50 mM HEPES, pH 7.6, 150 mM NaCl, 1% Triton X-100, 10 mM NaF, 20 mM Na~4~P~2~O~7~, 20 mM β-glycerol phosphate, 1 mM Na~3~VO~4~, 10 mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mM PMSF), incubated on ice for 20 min, and then centrifuged at 14000 × *g* for 10 min at 4°C. The supernatants were mixed with equal volume of 2x SDS-PAGE sample loading buffer and then denatured at 100°C for 10 min. The proteins were separated by SDS-PAGE gel, transferred to a nitrocellulose membrane, incubated with specific primary antibodies for overnight, and detected with horseradish peroxidase (HRP)-conjugated secondary antibodies by using a VersaDoc Image System (BioRad, Hercules, CA, USA).

Protein aggregation was determined using ProteoStat^TM^ Protein Aggregation Assay Kit (ENZ-51023-KP002) from Enzo Life Sciences International Inc. (Plymouth Meeting, PA, USA), following the manufacturer's instruction.

Statistical Analysis
--------------------

The data are presented as the means ± SD. The variable is normally distributed and differences between the groups were examined for statistical significance using analysis of variance (ANOVA), followed by a Newman--Keuls *post hoc* test. Differences were considered significant at *p* \< 0.05. All experiments were repeated at least four times with similar results. Representative western blot images were shown in Figures.

Results
=======

Curcumin Improved Palmitate-Induced Insulin Resistance in HUVECs
----------------------------------------------------------------

To figure out optimal experimental conditions for palmitate-induced insulin resistance, HUVECs were starved serum for 6 h and then treated with 0.25, 0.5, and 0.75 mM palmitate for 12 h, or 0.5 mM palmitate for 6, 12, and 18 h, followed by stimulation with 100 nM insulin for 10 min. We found that palmitate induced insulin resistance in time- and concentration-dependent manners, as demonstrated by decreased insulin-stimulated phosphorylation of Akt at Thr308 (**Figures [1A,B](#F1){ref-type="fig"}**). Because the reduction of Akt phosphorylation on Thr308 has statistical significance with 0.5 mM palmitate treatment for 12 h, this concentration and treatment duration of palmitate was used for further experimentation.

![**Curcumin mitigated palmitate-induced insulin resistance in HUVECs. (A)** Dose-response effect of palmitate (PA) on insulin (INS)-stimulated Akt T308 phosphorylation. **(B)** Time-response effect of PA on insulin-stimulated Akt T308 phosphorylation. **(C)** Attenuation of insulin resistance by curcumin (Cur) administration. **(D)** Effect of Cur on plasma membrane (PM) translocation of GLUT4. **(E)** Effect of Cur on 2-Deoxy-D-glucose (2-DG) uptake. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. indicated groups.](fphar-08-00148-g001){#F1}

When serum-starved HUVECs were treated with 0.5 mM palmitate in the presence or absence of 2.5, 5, 10, and 20 μM curcumin for 12 h, followed by stimulation with or without 100 nM insulin for 10 min, we found that curcumin supplementation significantly reverted insulin-stimulated phosphorylation of Akt Thr308 (**Figure [1C](#F1){ref-type="fig"}**). Consistent with these results, curcumin administration reversed the detrimental effects of palmitate on insulin-stimulated GLUT4 translocation on PM (**Figure [1D](#F1){ref-type="fig"}**) and 2-DG uptake (**Figure [1E](#F1){ref-type="fig"}**) in HUVECs cotreated with 0.5 mM palmitate and 10 μM curcumin under stimulation with 100 nM insulin for 10 min. These findings suggest that curcumin could sensitize insulin signaling in palmitate-treated HUVECs.

Palmitate Induced ER Stress and Adaptive Activation of the UPS and Autophagy
----------------------------------------------------------------------------

To elucidate the mechanism underlying palmitate-induced insulin resistance, we observed the potential impacts of palmitate on ER stress, the ubiquitin-proteasome system (UPS), and autophagy. HUVECs were starved serum for 6 h and then treated with 0.5 mM palmitate for 6, 12, and 18 h. As shown in **Figure [2](#F2){ref-type="fig"}**, palmitate treatment time-dependently increased the levels of ER stress markers (**Figure [2A](#F2){ref-type="fig"}**), the ratio of LC3-II to LC3-I (**Figure [2B](#F2){ref-type="fig"}**), and peptidase activities of 20S proteasome (**Figure [2C](#F2){ref-type="fig"}**), suggesting that palmitate activated ER stress, the UPS, and autophagy.

![**Palmitate enhanced ER stress and activated autophagy and the ubiquitin-proteasome system (UPS) in HUVECs. (A)** Effect of palmitate (PA) on ER stress markers. **(B)** Effect of PA on LC3 levels. **(C)** Effect of PA on peptidase activities of 20S proteasome. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group.](fphar-08-00148-g002){#F2}

When serum-starved HUVECs were pretreated with or without 5 mM 4-phenylbutyric acid (PBA), a potent ER stress inhibitor for 1 h and then incubated in the presence or absence of 0.5 mM palmitate for another 12 h, we found that PBA administration dramatically suppressed palmitate-enhanced LC3-II levels (**Figures [3A,B](#F3){ref-type="fig"}**), the ratio of LC3-II to LC3-I (**Figure [3A](#F3){ref-type="fig"}**), and peptidase activities of 20S proteasome (**Figure [3D](#F3){ref-type="fig"}**). PBA treatment also significantly decreased autophagy flux when compared with HUVECs treated with palmitate alone (**Figure [3C](#F3){ref-type="fig"}**). These results indicate that palmitate-induced activation of the UPS and autophagy were mediated by ER stress.

![**Inhibition of ER stress mitigated palmitate's impacts on autophagy and the UPS in HUVECs. (A,B)** Reduction of LC3 levels by ER stress inhibitor 4-phenylbutyrate (PBA). **(C)** Attenuation of autophagy flux by PBA. **(D)** Suppression of peptidase activities of 20S proteasome by PBA. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\$^*p* \> 0.05 vs. PA-treated group.](fphar-08-00148-g003){#F3}

Curcumin Suppressed Palmitate-Induced ER Stress
-----------------------------------------------

To figure out the potential impacts of curcumin treatment alone on HUVECs under normal culture condition, HUVECs were starved serum for 6 h and then treated with or without 10 μM curcumin for another 12 h. We found that curcumin treatment alone did not affect expressions of ER stress markers, protein aggregation, and phosphorylation of JNK Thr183 and IRS-1 Ser307 (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**), suggesting that curcumin did not affect ER stress in HUVECs under normal culture condition.

When serum-starved HUVECs were treated with or without 0.5 mM palmitate in the presence or absence of 10 μM curcumin for 12 h, we found that curcumin treatment markedly decreased the levels of ER stress markers (**Figure [4A](#F4){ref-type="fig"}**) as well as protein aggregation (**Figure [4B](#F4){ref-type="fig"}**), which were enhanced by palmitate treatment alone. Additionally, curcumin supplementation significantly inhibited palmitate-elevated expressions of phosphorylation of IRS-1 at Ser307 and JNK at Thr183 (**Figures [4C,D](#F4){ref-type="fig"}**), suggesting that curcumin could attenuate palmitate-induced ER stress and its downstream molecular events such as activation of JNK/IRS-1 signaling.

![**Curcumin mitigated palmitate-induced ER stress in HUVECs. (A)** Reduction of ER stress markers by curcumin (Cur). **(B)** Mitigation of protein aggregation by Cur. **(C)** Suppression of phosphorylated IRS-1 S307 and JNK Thr183 by Cur. **(D)** Quantification of phosphorylated IRS-1 and JNK in **(C)**. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group; ^\#^*p* \< 0.05 vs. PA-treated group.](fphar-08-00148-g004){#F4}

Curcumin Inhibited the UPS and Activated Autophagy in Palmitate-Treated HUVECs
------------------------------------------------------------------------------

To investigate the potential impacts of curcumin on the UPS and autophagy, the serum-starved HUVECs were treated with or without 0.5 mM palmitate in the presence or absence of 10 μM curcumin for 12 h. As shown in **Figure [5](#F5){ref-type="fig"}**, curcumin supplementation inhibited the UPS and enhanced autophagy, as evidenced by the suppressed peptidase activities of 20S proteasome (**Figure [5A](#F5){ref-type="fig"}**), increased LC3 levels and the ratio of LC3-II to LC3-1 (**Figures [5C,D](#F5){ref-type="fig"}**), as well as increased autophagy flux (**Figure [5E](#F5){ref-type="fig"}**), when compared with the group treated with palmitate alone. The total protein ubiquitination in curcumin-treated HUVECs had a little bit increase but no statistically significant changes (**Figure [5B](#F5){ref-type="fig"}**).

![**Curcumin inhibited the UPS and activated autophagy in HUVECs. (A)** Inhibition of peptidase activities of 20S proteasome by curcumin (Cur). **(B)** Effect of Cur on total protein ubiquitination. **(C)** Enhancement of LC3 levels by Cur. **(D,E)** Increased autophagy flux by Cur. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. control group; ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01 vs. PA-treated group.](fphar-08-00148-g005){#F5}

Inhibition of Autophagy Abolished the Beneficial Effect of Curcumin on Palmiated-Induced Insulin Resistance
-----------------------------------------------------------------------------------------------------------

To confirm the critical role of autophagy in mediating curcumin action on palmitate-induced insulin resistance, we silenced Atg5, an important regulator of autophagy by siRNA technique. The siRNA- and scramble control-infected HUVECs were starved serum for 6 h and then incubated with or without 0.5 mM palmitate in the presence or absence of 10 μM curcumin for another 12 h. We found that Atg5 knockdown abolished the beneficial effects of curcumin on the levels of ER stress markers (**Figure [6A](#F6){ref-type="fig"}**), exacerbated total protein ubiquitination (**Figure [6B](#F6){ref-type="fig"}**), and reversed protein aggregation (**Figure [6C](#F6){ref-type="fig"}**) under combined treatment with curcumin and palmitate, suggesting that Atg5 knockdown counteracted curcumin action on palmitate-induced ER stress. This conclusion was further confirmed by restored phosphorylation of IRS-1 at Ser307 and JNK at Thr183 in Atg5 knockdown HUVECs cotreated with curcumin and palmitate (**Figures [6D,E](#F6){ref-type="fig"}**).

![**Inhibition of autophagy abolished curcumin's impacts on ER stress in HUVECs. (A)** Effect of Atg5 knockdown on ER stress markers. **(B)** Effect of Atg5 knockdown on total protein ubiquitination. **(C)** Effect of Atg5 knockdown on protein aggregation. **(D)** Effect of Atg5 knockdown on phosphorylation of IRS-1 S307 and JNK Thr183. **(E)** Quantification of phosphorylated IRS-1 and JNK in **(D)**. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. indicated groups.](fphar-08-00148-g006){#F6}

We next observed the pathophysiological impacts of Atg5 knockdown on insulin signaling. Atg5 knockdown or scramble control HUVECs were starved serum for 6 h and then incubated with or without 0.5 mM palmitate in the presence or absence of 10 μM curcumin for another 12 h, followed by stimulation with 100 nM insulin for 10 min. As shown in **Figure [7](#F7){ref-type="fig"}**, Atg5 knockdown inhibited insulin-stimulated Akt-Thr308 phosphorylation (**Figure [7A](#F7){ref-type="fig"}**), GLUT4 PM translocation (**Figure [7B](#F7){ref-type="fig"}**), and 2-DG uptake (**Figure [7C](#F7){ref-type="fig"}**), when compared with group cotreated with curcumin and palmitate.

![**Inhibition of autophagy abolished curcumin's impacts on insulin resistance in HUVECs. (A)** Effect of Atg5 knockdown on insulin (INS)-stimulated Akt phosphorylation at Thr308 residue. **(B)** Effect of Atg5 knockdown on PM translocation of GLUT4. **(C)** Effect of Atg5 knockdown on 2-Deoxy-D-glucose (2-DG) uptake. *N* = 4. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 vs. indicated groups.](fphar-08-00148-g007){#F7}

Taken together, these results suggest that autophagy mediated curcumin's protection against palmitate-induced insulin resistance in HUVECs.

Discussion
==========

It has been suggested that increased concentration of plasma FFAs is an independent predictor of type 2 diabetes in individuals with impaired glucose tolerance ([@B44]). As one of most abundant FFAs in plasma, palmitate is closely associated with pathogenesis and progression of insulin resistance in insulin-target tissues and cells through inducing oxidative stress, ER stress, and inflammation ([@B31]; [@B44]). The previous studies have also demonstrated the inhibitory impacts of the elevated palmitate concentration on cell function and insulin signaling of endothelial cells ([@B33]; [@B43]; [@B19]). Consistent with these views, we found that palmitate induced insulin resistance in HUVECs in time- and concentration-dependent manners (**Figures [1A,B](#F1){ref-type="fig"}**). Moreover, palmitate-induced insulin resistance was accompanied with enhanced ER stress (**Figure [2A](#F2){ref-type="fig"}**), which has been suggested a major contributor to palmitate-induced insulin resistance through ER stress-activated JNK/IRS-1 pathway ([@B5]; [@B62]; [@B64]; [@B53]). Indeed, our results found that palmitate stimulated JNK/IRS-1 pathway (**Figures [4C,D](#F4){ref-type="fig"}**). Thus, our findings evidenced the involvement of ER stress in palmitate-induced insulin resistance of HUVECs.

Curcumin has been proven to enhance insulin receptor activity, sensitize insulin signaling, and inhibit inflammation and oxidative stress under insulin resistance condition, which are collectively responsible for improvement of insulin resistance by curcumin ([@B30]). In addition, curcumin displays a specific ability to ameliorate ER stress ([@B1]; [@B57]; [@B66]). In the present study, we found that curcumin supplementation significantly mitigated palmitate-induced insulin resistance (**Figures [1C--E](#F1){ref-type="fig"}**) and suppressed palmitate-stimulated ER stress/JNK/IRS-1 signaling in HUVECs (**Figure [4](#F4){ref-type="fig"}**), suggesting that curcumin reverted palmitate-induced insulin resistance of HUVECs by inhibiting ER stress.

It is well known that protein folding stress in ER may result in activation of ER membrane kinases such as PERK leading to UPR, aimed to maintain ER-derived quality control (ERQC) through activating ubiquitin-proteasome ERAD (I) and autophagy/lysosome ERAD (II) ([@B15]; [@B34]). Consistent with the previous studies showing the effective activation of autophagy and the UPS by palmitate ([@B67]; [@B25]; [@B27]; [@B52]; [@B42]), we found that palmitate treatment significant increased LC3-II levels and peptidase activities of 20S proteasome (**Figures [2B,C](#F2){ref-type="fig"}**). However, inhibition of ER stress by its specific inhibitor PBA abolished palmitate-stimulated activation of autophagy and the UPS, as evidenced by significant decreases of the ratio of LC3-II to LC3-I, autophagy flux, and peptidase activities of 20S proteasome (**Figure [3](#F3){ref-type="fig"}**), suggesting that palmitate-induced activation of autophagy and the UPS is an adaptive response to palmitate-stimulated ER stress ([@B52]).

The impacts of autophagy and the UPS on insulin signaling are complex and contradictory as well. Early studies have suggested that overactivation of either autophagy or the UPS negatively regulates insulin sensitivity ([@B3]; [@B36]; [@B47]), through reducing intracellular levels of some important molecules of insulin signaling pathway such as insulin receptor and IRS-1/2 in lysosome- or ubiquitin/proteasome-dependent machinery, respectively ([@B72]; [@B37]; [@B25]). However, the accumulating evidence has shown that both autophagy and the UPS are necessary for preserving insulin action. Inadequate autophagy contributes to endothelial dysfunction in patients with diabetes ([@B14]). Upregulation of autophagy has been demonstrated to improve insulin resistance, glucose intolerance, hyperglycemia, hyperlipidemia, and diabetic complications ([@B16]; [@B8]; [@B41]; [@B71]; [@B32]). Similarly, proteasome inhibition can significantly impair insulin signaling in 3T3-L1 adipocytes or further exacerbate insulin resistance in the myotubes derived from type 2 diabetic patients ([@B2]; [@B11]). These findings strongly indicate that autophagy and the UPS may be the targets for therapy of diabetes and diabetic complications. The different results of autophagy and the UPS on insulin signaling maybe caused by or associated with cell types or/and experimental conditions. In the present study, we observed an adaptive activation of autophagy and the UPS by palmitate treatment; however, intracellular abundances of key insulin signaling molecules such as insulin receptor, IRS-1, PDK1, and Akt remained unchanged (Data not shown). Combined with our results showing palmitate-induced insulin resistance (**Figures [1A,B](#F1){ref-type="fig"}**), our findings indicated that this adaptive regulation of autophagy and the UPS did not, at least in this case, affect insulin signaling.

The UPS and autophagy break down unnecessary or dysfunctional intracellular proteins through ubiquitin-proteasomal or lysosomal degradation process, respectively ([@B65]). The UPS impairment or inhibition will result in accumulation of misfolded and aggregated protein leading to compensative activation of autophagy ([@B35]; [@B26]; [@B65]), aimed to clear up the aggregated or misfolded proteins that were previously thought to be targeted exclusively by the UPS ([@B12]; [@B17]). Curcumin possesses the properties of proteasome inhibitor and autophagy inducer ([@B48]; [@B22]; [@B6]). In the present study, we found that curcumin administration significantly suppressed peptidase activities of 20S proteasome, and compensatively activated autophagy under palmitate treatment (**Figure [5](#F5){ref-type="fig"}**). Hence, the curcumin-induced inhibition of the UPS function did not significantly increase total protein ubiquitination (**Figure [5B](#F5){ref-type="fig"}**). In contrast, the compensative activation of autophagy would help to eliminate the aggregated proteins, as evidenced by decreased protein aggregation (**Figure [4B](#F4){ref-type="fig"}**). As discussed above, the UPS and autophagy play a critical role in maintaining ER protein homeostasis by removing most damaged or unfolded proteins as well as aggregated proteins ([@B15]; [@B34]). Inhibition of the UPS and autophagy will result in ER stress ([@B9]; [@B13]; [@B40]). Given that proteasome inhibition or impairment by curcumin compensatively activated autophagy (**Figure [5](#F5){ref-type="fig"}**), the curcumin-activated autophagy would therefore bring beneficial effects on protein aggregation and ER stress (**Figures [4A,B](#F4){ref-type="fig"}**), leading to inhibition of JNK/IRS-1 pathway (**Figures [4C,D](#F4){ref-type="fig"}**).

It is noteworthy that inhibition of autophagy will compromise the UPS function ([@B35]; [@B65]), which may cause disturbance of ER proteostasis leading to ER stress. Our previous study on 3T3-L1 adipocytes shows that autophagy inability suppresses proteasome activity, induces ER stress, and results in insulin resistance ([@B71]). Moreover, inhibition of the UPS function exacerbates autophagy inhibition-induced ER stress ([@B71]). Consistent with this research, we found that autophagy inhibition by silencing Atg5, a key regulatory protein of autophagy, attenuated proteasome activity and enhanced ER/JNK/IRS-1 pathway, leading to insulin resistance in HUVECs under normal culture condition (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). In addition, Atg5 knockdown abolished the favorable effects of curcumin on ER stress and JNK/IRS-1 pathway (**Figure [6](#F6){ref-type="fig"}**). Autophagy inhibition also restored protein aggregation (**Figure [6C](#F6){ref-type="fig"}**) and exacerbated total protein ubiquitination (**Figure [6B](#F6){ref-type="fig"}**), collectively responsible for restoration of ER stress by palmitate. As consequent, the curcumin-induced improvement of insulin resistance was abolished by the autophagy inhibition (**Figure [7](#F7){ref-type="fig"}**). These findings strongly suggest that autophagy plays a pivotal role in mediating curcumin action through maintaining ER proteostasis.

Taken together, our results revealed that curcumin heighten autophagy activity that is an essential regulator in the control of ER proteostasis (**Figure [8](#F8){ref-type="fig"}**). This regulation of ERQC compartment might be the basis of curcumin's beneficial activities in various pathophysiologic conditions of diabetes and diabetic complications including insulin resistance.

![**A schematic diagram of curcumin's impact on palmitate-induced insulin resistance of HUVECs**. Palmitate-induced disturbance of ER proteostasis results in ER stress/UPR and the adaptive activation of both the UPS and autophagy (black). The chronic ER stress/UPR leads to insulin resistance. Curcumin administration suppresses the UPS function and greatly activates autophagy, leading to restoration of ER proteostasis, inhibition of ER stress/UPR (red), and subsequent improvement of insulin sensitivity in HUVECs.](fphar-08-00148-g008){#F8}

Limitations
-----------

In the present study, we found that palmitate-induced insulin resistance was significantly attenuated by curcumin-stimulated compensative activation of autophagy but not by palmitate-induced adaptive activation of autophagy. However, we could not definitely explain mechanism underlying this phenomenon. In addition, ER stress, inflammation, and oxidative stress are all associated with the impacts of palmitate and curcumin on insulin signaling ([@B31]; [@B30]; [@B44]). Although it is well known that these stress processes are intimately interrelated and affect each other ([@B70]; [@B45]; [@B21]), the mechanisms linking ER stress to oxidative stress and inflammation were not investigated in this study. Not only are future studies required to observe how curcumin affect palmitate-induced inflammation and oxidative, but studies also are required to understand how interactions between ER stress, oxidative stress, and inflammation are involved in curcumin action.
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**Curcumin's impacts on ER stress in HUVECs under normal culture condition**. HUVECs were starved serum for 6 h and then treated with or without 10 μM curcumin for another 12 h. **(A)** Effects of curcumin on ER stress markers. **(B)** Effects of curcumin on protein aggregation. **(C)** Effect of curcumin on phosphorylation of IRS-1 S307 and JNK Thr183. *N* = 4. ^\#^*p* \> 0.05 vs. control group.
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**Atg5 knockdown induced insulin resistance in HUVECs under normal culture condition**. The siRNA- and scramble control-infected HUVECs were starved serum for 6 h and then stimulated with or without 100 nM insulin for 10 min. **(A)** Effects of Atg5 knockdown on chymotrypsin peptidase activities of 20S proteasome. **(B)** Effects of Atg5 knockdown on ER stress markers. **(C)** Effect of Atg5 knockdown on phosphorylation of IRS-1 S307 and JNK Thr183. **(D)** Effect of Atg5 knockdown on insulin (INS)-stimulated Akt phosphorylation at Thr308 residue. **(E)** Effect of Atg5 knockdown on 2-Deoxy-D-glucose (2-DG) uptake. *N* = 4. ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 vs. scramble control or indicated groups.
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